Michelson Diagnostics

Executive Summary

Michelson Diagnostics Ltd. (MDL) is a UK-based medical device company headquartered in Maidstone, England, that has developed the VivoSight Dx, a high-resolution Optical Coherence Tomography (OCT) system for real-time, in-vivo imaging of skin. Founded in 2006, the company focuses on providing dermatologists and researchers with a non-invasive tool to aid in the diagnosis of skin conditions, assessment of pathology, and monitoring of treatment response. The VivoSight Dx is designed to be cost-effective and practical for everyday clinical use, potentially reducing the need for biopsies and improving patient outcomes. As a private company, MDL operates in the diagnostics space with a clear mission to advance OCT technology in dermatology. Although financial details and employee count are not publicly available, the company's niche focus and proprietary technology position it as a specialized player in the medical imaging market.

Upcoming Catalysts (preview)

• Q4 2026FDA 510(k) Clearance for VivoSight Dx in the US Market70% success
• H1 2027Strategic Partnership or Distribution Agreement with a Major Dermatology Device Company50% success
• Q3 2026Publication of Clinical Study Demonstrating Superiority Over Biopsy in Suspected Skin Cancer Diagnosis60% success